Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935987 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
A Phase 1 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 1
- Development phase
- 166
- Enrollment target
NCT00935987: Completed Phase 1 study, sponsored by Sierra Oncology LLC - a GSK company.
NCT00935987 is a Phase 1 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 166 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (177% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00935987, a Phase 1 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 166 participants
- Enrollment target
Study Summary
This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
Interventions
- DRUG CYT387
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT00935987 record still lists
NCT00935987 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (177% higher).
The record links to 0 conditions, and to 1 intervention - of which CYT387 is the first listed.
NCT00935987 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00935987 about?
NCT00935987 is a clinical study titled "Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)". This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET.
What is the current status of trial NCT00935987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 166 participants. The study started on 2009-11. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00935987?
The interventions under investigation include: CYT387 (DRUG).
Who is sponsoring clinical trial NCT00935987?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00935987's enrollment target sits among peer trials
166 330th of 2000 higher than 1,669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia